Literature DB >> 2065696

The relationships between dose and concentration of tolbutamide and insulin and glucose responses in patients with non-insulin-dependent diabetes.

R E Ferner1, M L Antsiferov, A W Kelman, K G Alberti, M D Rawlins.   

Abstract

It is uncertain how the hypoglycaemic effect of sulphonylureas varies with drug concentration in patients with non-insulin-dependent diabetes mellitus. The inter-relationship of tolbutamide dosage and concentration, and glucose and insulin concentrations were therefore examined in 54 out-patients (the observational group) and in 20 patients studied under controlled conditions (the experimental group). In the observational group, tolbutamide concentration depended significantly on the daily dose, time from dose to sampling, body weight, and age. Blood glucose and insulin concentration were related, but were independent of tolbutamide concentration. In the experimental group, peak, but not pre-dose, tolbutamide concentration, depended on dose and on body mass index. Fasting and maximum post-prandial blood glucose concentration were positively correlated with maximum tolbutamide concentration, probably because tolbutamide dosage was highest in those with the poorest response. In the subset with a fasting blood glucose concentration of less than 8 mmol.l-1, neither glucose nor insulin concentrations depended significantly on tolbutamide concentrations. Tolbutamide concentration does not directly determine hypoglycaemic response in outpatients, and therapeutic monitoring of drug concentrations would not improve the management of such patients.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2065696     DOI: 10.1007/BF00280071

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  20 in total

1.  "Secondary failures" in the treatment of diabetes mellitus with tolbutamide and with phenformin.

Authors:  L P KRALL; R F BRADLEY
Journal:  Diabetes       Date:  1962       Impact factor: 9.461

2.  Secondary failure to treatment with oral antidiabetic agents in non-insulin-dependent diabetes.

Authors:  L C Groop; R Pelkonen; S Koskimies; G F Bottazzo; D Doniach
Journal:  Diabetes Care       Date:  1986 Mar-Apr       Impact factor: 19.112

3.  Tolbutamide, glucose, calcium, and somatostatin secretion.

Authors:  K Hermansen
Journal:  Acta Endocrinol (Copenh)       Date:  1982-01

Review 4.  Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM.

Authors:  R A DeFronzo
Journal:  Diabetes       Date:  1988-06       Impact factor: 9.461

5.  The effect of food on the bioavailability and pharmacodynamics of tolbutamide in diabetic patients.

Authors:  E J Antal; W R Gillespie; J P Phillips; K S Albert
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

6.  Serum tolbutamide and chlorpropamide concentrations in patients with diabetes mellitus.

Authors:  A Melander; G Sartor; E Wåhlin; B Scherstén; P O Bitzén
Journal:  Br Med J       Date:  1978-01-21

7.  Effect of food and tablet age on relative bioavailability and pharmacodynamics of two tolbutamide products.

Authors:  S C Olson; J W Ayres; E J Antal; K S Albert
Journal:  J Pharm Sci       Date:  1985-07       Impact factor: 3.534

8.  Radioimmunological determination of human C-peptide in serum.

Authors:  L G Heding
Journal:  Diabetologia       Date:  1975-12       Impact factor: 10.122

9.  Effects of total plasma concentration and age on tolbutamide plasma protein binding.

Authors:  J Adir; A K Miller; R E Vestal
Journal:  Clin Pharmacol Ther       Date:  1982-04       Impact factor: 6.875

10.  Lack of relationship between tolbutamide metabolism and debrisoquine oxidation phenotype.

Authors:  G F Peart; J Boutagy; G M Shenfield
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

View more
  3 in total

1.  Effect of magnesium hydroxide on the absorption and efficacy of tolbutamide and chlorpropamide.

Authors:  K T Kivistö; P J Neuvonen
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 2.  Problems and pitfalls of sulphonylurea therapy in older patients.

Authors:  D A Robertson; P D Home
Journal:  Drugs Aging       Date:  1993 Nov-Dec       Impact factor: 3.923

Review 3.  Comparative tolerability profiles of oral antidiabetic agents.

Authors:  A J Krentz; R E Ferner; C J Bailey
Journal:  Drug Saf       Date:  1994-10       Impact factor: 5.606

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.